Molecular and Trophic Mechanisms of Tumorigenesis

Endocrinology and Metabolism Clinics of North America

Volumn 37, Issue 1, 2008, Pages 23-50

  Levy, Andy ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATIC HYDROCARBON RECEPTOR; CELL CYCLE PROTEIN; CORTICOTROPIN;

ACROMEGALY; APOPTOSIS; CARCINOGENESIS; CARNEY COMPLEX; CELL COMMUNICATION; CELL CYCLE REGULATION; CELL PROLIFERATION; CLONOGENESIS; CORTICOTROPIN RELEASE; CUSHING SYNDROME; HORMONAL REGULATION; HUMAN; HYPOPHYSIS ADENOMA; MITOSIS; MULTIPLE ENDOCRINE NEOPLASIA; ONCOGENE; PHENOTYPE; PRIORITY JOURNAL; PROLACTINOMA; REVIEW; TUMOR SUPPRESSOR GENE;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; GTP-BINDING PROTEIN ALPHA SUBUNITS, GS; HUMANS; PHENOTYPE; PITUITARY NEOPLASMS;

EID: 38349096772     PISSN: 08898529     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ecl.2007.10.009     Document Type: Review

References (125)

1. Farrell W.E., and Clayton R.N. Molecular pathogenesis of pituitary tumors. Front Neuroendocrinol 21 3 (2000) 174-198
2. Levy A., and Lightman S.L. Molecular defects in the pathogenesis of pituitary tumors. Front Neuroendocrinol 24 2 (2003) 94-127
3. Scheithauer B.W., Gaffey T.A., Lloyd R.V., et al. Pathobiology of pituitary adenomas and carcinomas. Neurosurgery 59 2 (2006) 341-353
4. Hall W.A., Luciano M.G., Doppman J.L., et al. Pituitary magnetic resonance imaging in normal human volunteers: occult adenomas in the general population. Ann Intern Med 120 10 (1994) 817-820
5. Molitch M.E. Pituitary incidentalomas. Endocrinol Metab Clin North Am 26 (1997) 725-740
6. Ezzat S., Asa S.L., Couldwell W.T., et al. The prevalence of pituitary adenomas: a systematic review. Cancer 101 3 (2004) 613-619
7. Lindholm J., Juul S., Jorgensen J.O.L., et al. Incidence and late prognosis of Cushing's syndrome: a population-based study. J Clin Endocrinol Metab 86 1 (2001) 117-123
8. Scheithauer R.F., Young W.F.J., Horvath E., et al. Silent corticotroph carcinoma of the adenohypophysis: a report of five cases. Am J Surg Pathol 27 4 (2003) 477-486
9. Daly A.F., Rixhon M., Adam C., et al. High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium. J Clin Endocrinol Metab 91 12 (2006) 4769-4775
10. Console G.M., Gomez Dumm C.L., Brown O.A., et al. Sexual dimorphism in the age changes of the pituitary lactotrophs in rats. Mech Ageing Dev 95 3 (1997) 157-166
11. Donovan L.E., and Corenblum B. The natural history of the pituitary incidentaloma. Arch Intern Med 155 2 (1995) 181-183
12. Jeffcoate W.J., Pound N., Sturrock N.D.C., et al. Long-term follow-up of patients with hyperprolactinaemia. Clin Endocrinol (Oxf) 45 (1996) 299-303
13. Nammour G.M., Ybarra J., Hossain Naheedy M., et al. Incidental pituitary macroadenoma: a population-based study. Am J Med Sci 314 (1997) 287-291
14. Adler I., Barsi P., Czirjak S., et al. Rapid re-enlargement of a macroprolactinoma after initial shrinkage in a young woman treated with bromocriptine. Gynecol Endocrinol 20 6 (2005) 317-321
15. Burke C.W., Adams C.B., Esiri M.M., et al. Transsphenoidal surgery for Cushing's disease: does what is removed determine the endocrine outcome?. Clin Endocrinol (Oxf) 33 4 (1990) 525-537
16. Kruse A., Klinken L., Holck S., et al. Pituitary histology in Cushing's disease. Clin Endocrinol (Oxf) 37 3 (1992) 254-259
17. Denk C.C., Onderoglu S., Ilgi S., et al. Height of normal pituitary gland on MRI: differences between age groups and sexes. Okajimas Folia Anat Jpn 76 2-3 (1999) 81-87
18. Chanson P., Daujat F., Young J., et al. Normal pituitary hypertrophy as a frequent cause of pituitary incidentaloma: a follow-up study. J Clin Endocrinol Metab 86 7 (2001) 3009-3015
19. Schwartz J. Intercellular communication in the anterior pituitary. Endocr Rev 21 5 (2000) 488-513
20. Asa S.L., Penz G., Kovacs K., et al. Prolactin cells in the human pituitary. A quantitative immunocytochemical analysis. Arch Pathol Lab Med 106 7 (1982) 360-363
21. Dinc H., Esen F., Demirci A., et al. Pituitary dimensions and volume measurements in pregnancy and post partum. MR assessment. Acta Radiol 39 1 (1998) 64-69
22. Haggi E.S., Torres A.I., Maldonado C.A., et al. Regression of redundant lactotrophs in rat pituitary gland after cessation of lactation. J Endocrinol 111 3 (1986) 367-373
23. Chen J., Hersmus N., Van Duppen V., et al. The adult pituitary contains a cell population displaying stem/progenitor cell and early embryonic characteristics. Endocrinology 146 9 (2005) 3985-3998
24. Lepore D.A., Jokubaitis V.J., Simmons P.J., et al. A role for angiotensin-converting enzyme in the characterization, enrichment, and proliferation potential of adult muring pituitary colony-forming cells. Stem Cells 24 11 (2006) 2382-2390
25. Nolan L.A., Kavanagh E., Lightman S.L., et al. Anterior pituitary cell population control: basal cell turnover and the effects of adrenalectomy and dexamethasone treatment. J Neuroendocrinol 10 (1998) 207-215
26. McNicol A.M., and Carbajo-Perez E. Aspects of anterior pituitary growth, with special reference to corticotrophs. Pituitary 1 3-4 (1999) 257-268
27. Nolan L.A., Lunness H.R., Lightman S.L., et al. The effects of age and spontaneous adenoma formation on trophic activity in the rat pituitary gland: a comparison with trophic activity in the human pituitary and in human pituitary adenomas. J Neuroendocrinol 11 (1999) 393-401
28. Taniguchi Y., Tamatani R., Yasutaka S., et al. Proliferation of pituitary corticotrophs following adrenalectomy as revealed by immunocytochemistry combined with bromodeoxyuridine-labeling. Histochem Cell Biol 103 (1995) 127-130
29. Nolan L.A., and Levy A. A population of non-LH/non-ACTH-positive cells in the male rat anterior pituitary responds mitotically to both gonadectomy and adrenalectomy. J Neuroendocrinol 18 9 (2006) 655-661
30. Nolan L.A., and Levy A. Anterior pituitary trophic responses to dexamethasone withdrawal and repeated dexamethasone exposures. J Endocrinol 169 (2001) 263-270
31. Potten C.S., Schofield R., and Lajtha L.G. A comparison of cell replacement in bone marrow, testis and three regions of surface epithelium. Biochim Biophys Acta 560 1 (1979) 281-299
32. Fuchs E., and Segre J.A. Stem cells: a new lease on life. Cell 100 (2000) 143-155
33. Nolan L.A., Thomas C.K., and Levy A. Permissive effects of thyroid hormones on rat anterior pituitary mitotic activity. J Endocrinol 180 (2004) 35-43
34. Taniguchi Y., Yasutaka S., Kominami R., et al. Proliferation and differentiation of rat anterior pituitary cells. Anat Embryol (Berl) 206 1-2 (2002) 1-11
35. Park S., Kamegai J., and Kineman R.D. Role of glucocorticoids in the regulation of pituitary somatostatin receptor subtype (sst1-sst5) mRNA levels: evidence for direct and somatostatin-mediated effects. Neuroendocrinology 78 3 (2003) 1163-1175
36. Nolan L.A., Schmid H.A., and Levy A. Octreotide and the novel multi-receptor ligand somatostatin receptor agonist pasireotide (SOM230), block the adrenalectomy-induced increase in mitotic activity in male rat anterior pituitary. Endocrinology 148 (2007) 2821-2827
37. Nolan L.A., Thomas C.K., and Levy A. Pituitary mitosis and apoptotic responsiveness following adrenalectomy are independent of hypothalamic paraventricular nucleus CRH input. J Endocrinol 181 3 (2004) 521-529
38. Nolan L.A., and Levy A. The effects of testosterone and estrogen on gonadectomized and intact male rat anterior pituitary mitotic and apoptotic activity. J Endocrinol 188 3 (2006) 387-396
39. Sakuma S., Shirasawa N., and Yoshimura F. A histometrical study of immunohistochemically identified mitotic adenohypophysial cells in immature and mature castrated rats. J Endocrinol 100 (1984) 323-328
40. Inoue K., Tanaka S., and Kurosumi K. Mitotic activity of gonadotropes in the anterior pituitary of the castrated male rat. Cell Tissue Res 240 2 (1985) 271-276
41. Nagesser S.K., van Seters A.P., Kievit J., et al. Long-term results of total adrenalectomy for Cushing's disease. World J Surg 24 1 (2000) 108-113
42. Aoki M.P., Aoki A., and Maldonado C.A. Sexual dimorphism of apoptosis in lactotrophs induced by bromocryptine. Histochem Cell Biol 116 3 (2001) 215-222
43. Nunez L., Villalobos C., Senovilla L., et al. Multifunctional cells of mouse anterior pituitary reveal a striking sexual dimorphism. J Physiol 549 Pt 3 (2003) 835-843
44. Scheithauer B.W., Horvath E., Kovacs K., et al. Plurihormonal pituitary adenomas. Semin Diagn Pathol 3 (1986) 69-82
45. Ho D.M., Hsu C.Y., Ting L.T., et al. Plurihormonal pituitary adenomas: immunostaining of all pituitary hormones is mandatory for correct classification. Histopathology 39 3 (2001) 310-319
46. Furuhata S., Kameya T., Otani M., et al. Prolactin presents in all pituitary tumors of acromegalic patients. Hum Pathol 24 1 (1993) 10-15
47. Ma W., Ikeda H., and Yoshimoto T. Clinicopathologic study of 123 cases of prolactin-secreting pituitary adenomas with special reference to multihormone production and clonality of the adenomas. Cancer 95 2 (2002) 258-266
48. Villalobos C., Nunez L., Frawley L.S., et al. Multi-responsiveness of single anterior pituitary cells to hypothalamic-releasing hormones: a cellular basis for paradoxical secretion. Proc Natl Acad Sci USA 94 25 (1997) 14132-14137
49. Simpson D.J., McNicol A.M., Murray D.C., et al. Molecular pathology shows p16 methylation in nonadenomatous pituitaries from patients with Cushing's disease. Clin Cancer Res 10 5 (2004) 1780-1788
50. Peri A., Bemporad D., Parenti G., et al. Cushing's syndrome due to intermittent ectopic ACTH production showing a temporary remission during a pulmonary infection. Eur J Endocrinol 145 (2001) 605-611
51. Gartler S.M., and Riggs A.D. Mammalian X-chromosome inactivation. Annu Rev Genet 17 (1983) 155-190
52. Tonon L., Bergamaschi G., Dellavecchia C., et al. Unbalanced X-chromosome inactivation in haemopoietic cells from normal women. Br J Haematol 102 4 (1998) 996-1003
53. Levy A. Monoclonality of endocrine tumours: what does it mean?. Trends Endocrinol Metab 12 7 (2001) 301-307
54. Schmidt G.H., and Mead R. On the clonal origin of tumours-lessons from studies of intestinal epithelium. Bioessays 12 1 (1990) 37-40
55. Woodruff M.F., Ansell J.D., Forbes G.M., et al. Clonal interaction in tumours. Nature 299 5886 (1982) 822-824
56. Clayton R.N., Pfeifer M., Atkinson A.B., et al. Different patterns of allelic loss (loss of heterozygosity) in recurrent human pituitary tumors provide evidence for multiclonal origins. Clin Cancer Res 6 10 (2000) 3973-3982
57. Clayton R.N., and Farrell W.E. Clonality of pituitary tumours: more complicated than initially envisaged?. Brain Pathol 11 3 (2001) 313-327
58. Zahedi A., Booth G.L., Smyth H.S., et al. Distinct clonal composition of primary and metastatic adrencorticotrophic hormone-producing pituitary carcinoma. Clin Endocrinol (Oxf) 55 (2001) 549-556
59. Busque L., Mio R., Mattioli J., et al. Nonrandom X-inactivation patterns in normal females: lyonization ratios vary with age. Blood 88 1 (1996) 59-65
60. Tsai Y.C., Simoneau A.R., Spruck C.H.R., et al. Mosaicism in human epithelium: macroscopic monoclonal patches cover the urothelium. J Urol 153 5 (1995) 1698-1700
61. Schwartz S.M., and Murry C.E. Proliferation and the monoclonal origins of atherosclerotic lesions. Annu Rev Med 49 (1998) 437-460
62. Tiltman A.J. Smooth muscle neoplasms of the uterus. Curr Opin Obstet Gynecol 9 1 (1997) 48-51
63. Aihara T., Noguchi S., Sasaki Y., et al. Does monoclonality mean malignancy. Hepatology 24 6 (1996) 1550
64. Arnold A., Brown M.F., Urena P., et al. Monoclonality of parathyroid tumors in chronic renal failure and in primary parathyroid hyperplasia. J Clin Invest 95 5 (1995) 2047-2053
65. Tominaga Y., Kohara S., Namii Y., et al. Clonal analysis of nodular parathyroid hyperplasia in renal hyperparathyroidism. World J Surg 20 7 (1996) 744-750
66. Aeschimann S., Kopp P.A., Kimura E.T., et al. Morphological and functional polymorphism within clonal thyroid nodules. J Clin Endocrinol Metab 77 3 (1993) 846-851
67. Levy A. Is monoclonality in pituitary adenomas synonymous with neoplasia?. Clin Endocrinol (Oxf) 52 (2000) 393-397
68. Herman V., Fagin J., Gonsky E., et al. Clonal origins of pituitary adenomas. J Clin Endocrinol Metab 71 (1990) 1427-1433
69. Alexander J.M., Biller B.M., Bikkal H., et al. Clinically nonfunctioning pituitary tumors are monoclonal in origin. J Clin Invest 86 (1990) 336-340
70. Biller B.M.K., Alexander J.M., Zervas N.T., et al. Clonal origins of adrenocorticotropin-secreting pituitary tissue in Cushing's disease. J Clin Endocrinol Metab 75 5 (1992) 1303-1309
71. Schulte H.M., OldFFfield E.H., Allolio B., et al. Clonal composition of pituitary adenomas in patients with Cushing's disease: determination by X-chromosome inactivation analysis. J Clin Endocrinol Metab 73 (1991) 1302-1308
72. Gicquel C., Le Bouc Y., Luton J.P., et al. Monoclonality of corticotroph macroadenomas in Cushing's disease. J Clin Endocrinol Metab 75 2 (1992) 472-475
73. Sotillo R., Hernando E., Díaz-Rodríguez E., et al. Mad2 overexpression promotes aneuploidy and tumorigenesis in mice. Cancer Cell 11 1 (2007) 9-23
74. Anniko M., Tribukait B., and Wersall J. DNA ploidy and cell phase in human pituitary tumors. Cancer 53 8 (1984) 1708-1713
75. Gaffey T.A.J., Scheithauer B.W., Leech R.W., et al. Pituitary adenoma: a DNA flow cytometric study of 192 clinicopathologically characterized tumors. Clin Neuropathol 24 2 (2005) 56-63
76. Pegolo G., Buckwalter J.G., Weiss M.H., et al. Pituitary adenomas. Correlation of the cytologic appearance with biologic behavior. Acta Cytol 39 5 (1995) 887-892
77. Losa M., Franzin A., Mangili F., et al. Proliferation index of nonfunctioning pituitary adenomas: correlations with clinical characteristics and long-term follow-up results. Neurosurgery 47 6 (2000) 1313-1318
78. Neufeld T.P., de la Cruz A.F., Johnston L.A., et al. Coordination of growth and cell division in the Drosophila wing. Cell 93 7 (1998) 1183-1193
79. Stowers R.S., and Schwarz T.L. A genetic method for generating Drosophila eyes composed exclusively of mitotic clones of a single genotype. Genetics 152 4 (1999) 1631-1639
80. O'Neill E.E., Matallanas D., and Kolch W. Mammalian sterile 20-like kinases in tumor suppression: an emerging pathway. Cancer Res 65 13 (2005) 5485-5487
81. St John M.A., Tao W., Fei X., et al. Mice deficient of Lats1 develop soft-tissue sarcomas, ovarian tumours and pituitary dysfunction. Nat Genet 21 (1999) 182-186
82. Carney J.A. The Carney complex (myxomas, spotty pigmentation, endocrine overactivity, and schwannomas). Dermatol Clin 13 1 (1995) 19-26
83. Daly A.F., Jaffrain-Rea M.L., Ciccarelli A., et al. Clinical characterization of familial isolated pituitary adenomas. J Clin Endocrinol Metab 91 9 (2006) 3316-3323
84. Vierimaa O., Georgitsi M., Lehtonen R., et al. Pituitary adenoma predisposition caused by germline mutations in the AIP gene. Science 312 5777 (2006) 1228-1230
85. Lytras A., and Tolis G. Growth hormone-secreting tumors: genetic aspects and data from animal models. Neuroendocrinology 83 (2006) 166-178
86. Frohman L.A., and Eguchi K. Familial acromegaly. Growth Horm IGF Res 14 Suppl A (2004) S90-S96
87. Soares B., Eguchi K., and Frohman L.A. Tumor deletion mapping on chromosome 11q13 in eight families with isolated familial somatotropinoma and in 15 sporadic somatotropinomas. J Clin Endocrinol Metab 90 12 (2005) 6580-6587
88. Komminoth P., Roth J., Muletta-Feurer S., et al. RET proto-oncogene point mutations in sporadic neuroendocrine tumors. J Clin Endocrinol Metab 81 6 (1996) 2041-2046
89. Yoshimoto K., Tanaka C., Moritani M., et al. Infrequent detectable somatic mutations of the RET and glial cell line-derived neurotrophic factor (GDNF) genes in human pituitary adenomas. Endocr J 46 1 (1999) 199-207
90. Iwata T., Yamada S., Mizusawa N., et al. The aryl hydrocarbon receptor-interacting protein gene is rarely mutated in sporadic GH-secreting adenoma. Clin Endocrinol (Oxf) 66 4 (2007) 499-502
91. Hillegass J.M., Murphy K.A., Villano C.M., et al. The impact of aryl hydrocarbon receptor signaling on matrix metabolism: implications for development and disease. Biol Chem 387 9 (2006) 1159-1173
92. Georgitsi M., Raitila A., Karhu A., et al. Molecular diagnosis of pituitary adenoma predisposition caused by aryl hydrocargon receptor-interacting protein gene mutations. Proc Natl Acad Sci USA 104 10 (2007) 4101-4105
93. Yu R., Bonert V., Saporta I., et al. Aryl hydrocarbon receptor interacting protein variants in sporadic pituitary adenomas. J Clin Endocrinol Metab 91 (2006) 5126-5129
94. Toledo R.A., Lourenco D.M.J., Liberman B., et al. Germline mutation in the Aryl Hydrocarbon Receptor Interacting Protein (AIP) Gene in Familial Somatotropinoma. J Clin Endocrinol Metab 92 5 (2007) 1934-1937
95. Barlier A., Vanbellinghen J.F., Daly A.F., et al. Mutations in the aryl hydrocarbon receptor interacting protein gene are not highly prevalent among subjects with sporadic pituitary adenomas. J Clin Endocrinol Metab 92 5 (2007) 1952-1955
96. Daly A.F., Vanbellinghen J.F., Khoo S.K., et al. Aryl hydrocarbon receptor interacting protein gene mutations in familial isolated pituitary adenomas: analysis in 73 families. J Clin Endocrinol Metab 92 5 (2007) 1891-1896
97. Georgitsi M., Karhu A., Winqvist R., et al. Mutation analysis of aryl hydrocarbon receptor interacting protein (AIP) gene in colorectal, breast, and prostate cancer. Br J Cancer 96 2 (2007) 352-356
98. Sherr C.J., and Roberts J.M. Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev 9 10 (1995) 1149-1163
99. Zhang X., Horwitz G.A., Heaney A.P., et al. Pituitary tumor transforming gene (PTTG) expression in pituitary adenomas. J Clin Endocrinol Metab 84 2 (1999) 761-767
100. Kanakis D., Kirches E., Mawrin C., et al. Promoter mutations are no major cause of PTTG overexpression in pituitary adenomas. Clin Endocrinol (Oxf) 58 2 (2003) 151-155
101. Burton F.H., Hasel K.W., Bloom F.E., et al. Pituitary hyperplasia and gigantism in mice caused by a cholera toxin transgene. Nature 350 (1991) 74-77
102. Bertherat J., Chanson P., and Montminy M. The cyclic adenosine 3′,5′-monophosphate-responsive factor CREB is constitutively activated in human somatotroph adenomas. Mol Endocrinol 9 7 (1995) 777-783
103. Hamacher C., Brocker M., Adams E.F., et al. Overexpression of stimulatory G protein alpha-subunit is a hallmark of most human somatotrophic pituitary tumours and is associated with resistance to GH-releasing hormone. Pituitary 1 1 (1998) 13-23
104. Spada A., Arosio M., Bochicchio D., et al. Clinical, biochemical, and morphological correlates in patients bearing growth hormone-secreting pituitary tumors with or without constitutively active adenylyl cyclase. J Clin Endocrinol Metab 71 6 (1990) 1421-1426
105. Peri A., Conforti B., Baglioni-Peri S., et al. Expression of cyclic adenosine 3′,5′-monophosphate (cAMP)-responsive element binding protein and inducible-cAMP early repressor genes in growth hormone-secreting pituitary adenomas with or without mutations of the Gsalpha gene. J Clin Endocrinol Metab 86 5 (2001) 2111-2117
106. Williamson E.A., Ince P.G., Harrison D., et al. G-protein mutations in human pituitary adrenocorticotrophic hormone-secreting adenomas. Eur J Clin Invest 25 2 (1995) 128-131
107. Tordjman K., Stern N., Ouaknine G., et al. Activating mutations of the Gs alpha-gene in nonfunctioning pituitary tumors. J Clin Endocrinol Metab 77 3 (1993) 765-769
108. Abbass S.A., Asa S.L., and Ezzat S. Altered expression of fibroblast growth factor receptors in human pituitary adenomas. J Clin Endocrinol Metab 82 4 (1997) 1160-1166
109. McCabe C.J., Khaira J.S., Boelaert K., et al. Expression of pituitary tumour transforming gene (PTTG) and fibroblast growth factor-2 (FGF-2) in human pituitary adenomas: relationships to clinical tumour behaviour. Clin Endocrinol (Oxf) 58 2 (2003) 141-150
110. Fujiwara K., Ikeda H., and Yoshimoto T. Abnormalities in expression of genes, mRNA, and proteins of transforming growth factor-beta receptor type I and type II in human pituitary adenomas. Clin Neuropathol 17 1 (1998) 19-26
111. Asa S.L., and Ezzat S. The cytogenesis and pathogenesis of pituitary adenomas. Endocr Rev 19 6 (1998) 798-827
112. Hashimoto K., Koga M., Motomura T., et al. Identification of alternatively spliced messenger ribonucleic acid encoding truncated growth hormone-releasing hormone receptor in human pituitary adenomas. J Clin Endocrinol Metab 80 10 (1995) 2933-2939
113. Jorge B.H., Agarwal S.K., Lando V.S., et al. Study of the multiple endocrine neoplasia type 1, growth hormone-releasing hormone receptor, Gs alpha, and Gi2 alpha genes in isolated familial acromegaly. J Clin Endocrinol Metab 86 2 (2001) 542-544
114. Dimaraki E.V., Chandler W.F., Brown M.B., et al. The role of endogenous growth hormone-releasing hormone in acromegaly. J Clin Endocrinol Metab 91 6 (2006) 2185-2190
115. Thapar K., Kovacs K., Stefaneanu L., et al. Overexpression of the growth-hormone-releasing hormone gene in acromegaly-associated pituitary tumors. An event associated with neoplastic progression and aggressive behavior. Am J Pathol 151 3 (1997) 769-784
116. Karl M., Lamberts S.W., Koper J.W., et al. Cushing's disease preceded by generalized glucocorticoid resistance: clinical consequences of a novel, dominant-negative glucocorticoid receptor mutation. Proc Assoc Am Physicians 108 4 (1996) 296-307
117. Karl M., Von Wichert G., Kempter E., et al. Nelson's syndrome associated with a somatic frame shift mutation in the glucocorticoid receptor gene. J Clin Endocrinol Metab 81 1 (1996) 124-129
118. Ballare E., Persani L., Lania A.G., et al. Mutation of somatostatin receptor type 5 in an acromegalic patient resistant to somatostatin analog treatment. J Clin Endocrinol Metab 86 8 (2001) 3809-3814
119. Filopanti M., Ballare E., Lania A.G., et al. Loss of heterozygosity at the SS receptor type 5 locus in human GH- and TSH-secreting pituitary adenomas. J Endocrinol Invest 27 10 (2004) 937-942
120. Greenman Y., and Melmed S. Heterogeneous expression of two somatostatin receptor subtypes in pituitary tumors. J Clin Endocrinol Metab 78 2 (1994) 398-403
121. Corbetta S., Ballare E., Mantovani G., et al. Somatostatin receptor subtype 2 and 5 in human GH-secreting pituitary adenomas: analysis of gene sequence and mRNA expression. Eur J Clin Invest 31 3 (2001) 208-214
122. Murabe H., Shimatsu A., Ihara C., et al. Expression of somatostatin receptor (SSTR) subtypes in pituitary adenomas: quantitative analysis of SSTR2 mRNA by reverse transcription-polymerase chain reaction. J Neuroendocrinol 8 8 (1996) 605-610
123. Caccavelli L., Feron F., Morange I., et al. Decreased expression of the two D2 dopamine receptor isoforms in bromocriptine-resistant prolactinomas. Neuroendocrinology 60 3 (1994) 314-322
124. Kaptain G.J., Simmons N.E., Alden T.D., et al. Estrogen receptors in prolactinomas: a clinico-pathological study. Pituitary 1 2 (1999) 91-98
125. Gittoes N.J., McCabe C.J., Sheppard M.C., et al. Estrogen receptor beta mRNA expression in normal and adenomatous pituitaries. Pituitary 1 2 (1999) 99-104